Karuna Therapeutics, Inc. KRTX
Set alert
329.83 0.00 0.00%
At close · Mar 15
329.75 Day range 329.97
52-week range unavailable
- Open
- 329.75
- Prev close
- 329.83
- Mkt cap
- 12.60B
- Vol
- 1.28M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 329.75
- High
- 329.97
- Forward P/E
- -36.49
- Beta
- 1.15
- Short ratio
- 3.60
- Inst. own
- 86.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 2, 2024
- 50-d avg
- 317.71
- 200-d avg
- 230.08
- 1y target
- 324.17
Analyst view
Consensus: hold
Hold
Price target (mean) 324.17 -1.7% downside
Now 329.83
- Target (low)
- 260.00
- Target (mean)
- 324.17
- Target (high)
- 330.00
Recommendation trend
- 1 month ago 18
- 2 months ago 18
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -3.06 | -3.50 – -2.82 | -2.80 | -9.3% | 340.00K | 0.0% | 6 |
| Next quarter | -3.26 | -3.62 – -3.01 | -2.75 | -18.5% | 940.00K | 0.0% | 6 |
| Current year | -11.54 | -14.94 – -5.49 | -11.73 | +1.6% | 40.17M | +6042.2% | 9 |
| Next year | -9.04 | -12.84 – -3.47 | -11.54 | +21.7% | 254.72M | +534.1% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 27, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 7, 2023 | B of A Securities | Maintained | Buy | Buy |
| Aug 21, 2023 | Cantor Fitzgerald | Reiterated | Neutral | Neutral |
| Aug 21, 2023 | Wells Fargo | Initiated | — | Overweight |
| Aug 3, 2023 | Morgan Stanley | Reiterated | Overweight | Overweight |
| Aug 3, 2023 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 3, 2023 | Mizuho | Maintained | Buy | Buy |
| Aug 3, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 19, 2023 | Morgan Stanley | Initiated | — | Overweight |
| Jul 12, 2023 | William Blair | Maintained | Outperform | Outperform |
| Jun 4, 2023 | JP Morgan | Maintained | Overweight | Overweight |
| Jun 1, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 31, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| May 15, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 7, 2023 | Oppenheimer | Reiterated | — | Outperform |
| May 7, 2023 | Mizuho | Maintained | — | Buy |
| May 7, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| May 4, 2023 | Wells Fargo | Maintained | — | Overweight |
| May 4, 2023 | RBC Capital | Maintained | — | Outperform |
| May 4, 2023 | Citigroup | Maintained | — | Buy |
| Mar 27, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Mar 20, 2023 | JMP Securities | Reiterated | — | Market Outperform |
| Mar 20, 2023 | Wedbush | Maintained | — | Outperform |
| Mar 7, 2023 | Cantor Fitzgerald | Initiated | — | Neutral |
| Mar 1, 2023 | Wells Fargo | Reiterated | — | Overweight |
| Feb 26, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 31, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jan 26, 2023 | UBS | Initiated | — | Neutral |
| Jan 4, 2023 | Piper Sandler | Initiated | — | Overweight |
| Nov 3, 2022 | Wells Fargo | Maintained | — | Overweight |